GlobeNewswire Inc.··Alx Oncology Holdings Inc.ALX Oncology Narrows Losses, Secures Funding as Clinical Pipeline Advances
ALX Oncology reduced losses and secured $150M in funding, extending cash runway to mid-2028. The company advances its clinical pipeline with CD47 biomarker validation for its cancer therapies.
ALXOclinical trialsevorpacept